CLEVELAND — May 17, 2018 — OptiKira, LLC, a privately-held biotechnology startup developing drugs that inhibit the unfolded protein response (UPR) with applications in a variety of diseases, including retinitis pigmentosa, type I diabetes, idiopathic pulmonary fibrosis (IPF), amyotrophic lateral sclerosis (ALS), and immuno-oncology announced today that it achieved a significant proof-of-principle milestone.
CLEVELAND, April 26, 2017 - OptiKira founders Dr. Feroz Papa (UCSF), Dr. Bradley Backes (UCSF) and Dr. Dustin Maly (University of Washington) have published research showing that direct targeting of IRE1α, using mono-selective KIRA8, reverses autoimmune diabetes in mouse models. Read full Cell Metabolism article here.
OptiKira has been awarded a $498,500 grant to support the development of their platform technology for the treatment of ALS (Lou Gehrig's disease). The company's technology prevents progressive cell death and is being developed for a range of degenerative diseases including ALS, retinitis pigmentosa and diabetes. OptiKira is based on the discoveries of Harrington Scholars from UCSF and technology licensed from UCSF and the University of Washington.
Arix Bioscience Limited (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today it has provided development capital to OptiKira, LLC (OptiKira), an early stage company developing drugs to help prevent blindness.
Extensive research by OptiKira’s founders has helped in defining the biological pathway leading to progressive cell death that characterises diseases such as retinitis pigmentosa (RP), diabetes and amyotrophic lateral sclerosis (ALS).
OptiKira has been awarded two NIH grants to support the development of novel therapeutics that prevent cell death caused by misfolded or unfolded proteins. The company's technology has application for diseases such as retinitis pigmentosa, diabetes, and ALS.
OptiKira, launched by BioMotiv, is based on technology from Harrington Scholars at University of California, San Francisco, and collaborators from the University of Washington.
BioMotiv, a drug development accelerator associated with The Harrington Project, the University of California, San Francisco (UCSF), and University of Washington, Seattle, are announcing the formation of OptiKira, a platform company that will develop small molecule therapeutics that prevent cell death in pathologies caused by misfolded or unfolded proteins.